← Back to Clinical Trials
Recruiting NCT06925308

NCT06925308 Course of Face-to-face Interactions in Adults With Autism

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06925308
Status Recruiting
Phase
Sponsor UMC Utrecht
Condition Autism Spectrum Disorder (ASD)
Study Type INTERVENTIONAL
Enrollment 54 participants
Start Date 2025-02-03
Primary Completion 2025-09-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type INTERVENTIONAL
Interventions
Conversation

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 54 participants in total. It began in 2025-02-03 with a primary completion date of 2025-09-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This research explores how adults with autism make eye contact during formal and informal interactions; to what extent the nature of a conversation influences how eye contact is made in terms of length, frequency and overall presentation. Also what physiological responses to eye contact are, in order to determine to what extent eye contact leads to an increased, decreased or unchanged stress level. In addition, to gain insight into the similarities and differences in how people with ASD respond to eye contact of others compared to their own eye contact.

Eligibility Criteria

Inclusion criteria * Neurotypical adults and adults with an ASD, determined according to an internationally recognized classification system. * Able to understand the instructions. * Motivation to participate in research. Exclusion criteria * No good command of the Dutch language. * Use of alcohol and/or recreational drugs during the research. * Mentally too unstable to participate in the research. * Familiarity with treatment in the VGZ.

Contact & Investigator

Central Contact

Jos Boer, MSc

✉ j.c.boer-30@umcutrecht.nl

📞 +31 6 20083507

Principal Investigator

Nynke Boonstra, Professor

STUDY CHAIR

UMC Utrecht

Frequently Asked Questions

Who can join the NCT06925308 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Autism Spectrum Disorder (ASD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06925308 currently recruiting?

Yes, NCT06925308 is actively recruiting participants. Contact the research team at j.c.boer-30@umcutrecht.nl for enrollment information.

Where is the NCT06925308 trial being conducted?

This trial is being conducted at Deventer, Netherlands.

Who is sponsoring the NCT06925308 clinical trial?

NCT06925308 is sponsored by UMC Utrecht. The principal investigator is Nynke Boonstra, Professor at UMC Utrecht. The trial plans to enroll 54 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology